Truist raises Chemours stock rating to Buy, sets $27 price target

On Monday, Truist Securities began coverage on Chemours shares (NYSE:CC) with a Buy rating and a price target of $27.00. The $2.85 billion market cap company, which currently trades at a P/E ratio of 37.3, offers investors a notable dividend yield of 5.08%. According to InvestingPro data, the company's next earnings report is scheduled for February 6, 2025. The firm's analysts are optimistic about the company's potential for significant earnings growth in the years 2025-26. This positive outlook is attributed to the expected continued growth at accretive margins for Chemours' next-generation refrigerant Opteon franchise. Additionally, Truist Securities believes that the market consensus underestimates the potential for an earnings recovery in the company's Titanium Dioxide (TiO2) segment, which has recently underperformed.

The analysts at Truist Securities see a potential upside to the current valuation of Chemours. They cite the new management team's plans to optimize the company's cost structure and to target growth in higher-value product applications as reasons for their rating. InvestingPro analysis suggests the stock is slightly overvalued at current levels, with additional metrics and insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of what really matters for investors. In their view, these strategic moves by Chemours' management could lead to an increase in the company's stock value.

The coverage initiation by Truist Securities comes with a statement from the firm, explaining their rationale behind the rating and price target. "We believe CC is positioned for significant earnings growth in 2025-26 driven by continued growth at accretive margins for its next-gen refrigerant Opteon franchise, and believe that consensus estimates are overly conservative regarding the potential for earnings recovery in the recently underperforming TiO2 segment," said the analyst from Truist Securities.

The firm further elaborates on their position, adding, "We see upside to current valuation as the new management team implements its plans to optimize the company's cost structure and target growth in higher-value product applications."

Truist Securities' initiation of coverage with a Buy rating and a $27 price target reflects their confidence in Chemours' future performance and strategic initiatives. The firm's analysis suggests that Chemours is on a path to recovery and growth, which may not be fully recognized by the broader market at this time. With annual revenue of $5.75 billion and significant operating challenges including a high debt burden, investors seeking deeper insights can access comprehensive financial health scores and additional ProTips through InvestingPro's detailed analysis tools.

In other recent news, Chemours Company has been making strategic moves that have grabbed the attention of investors. The chemical manufacturer recently appointed Damián Gumpel as the President of its Titanium Technologies business segment. Gumpel's experience in the chemical industry, including leadership roles at Olin (NYSE:OLN) Corporation and Dow Inc (NYSE:DOW)., is expected to fortify Chemours' Titanium Technologies business.

In parallel, Diane Iuliano Picho has been named Chief Enterprise Enablement Officer, a role that will see her leading the Enterprise Enablement unit to improve operational processes across the company. These leadership changes are part of Chemours' ongoing efforts to strengthen its market position.

Recent developments also include Chemours' partnership with The PCC Group to construct a new chlor-alkali facility in DeLisle, Mississippi. The facility, with a capacity of 340 kilotons, is expected to produce an estimated 10-15% of the U.S. merchant chlorine market. Despite this, KeyBanc Capital Markets has maintained its Overweight rating on Olin Corporation, a significant player in the same market.

In addition to these developments, Chemours has added Joseph Kava, Google (NASDAQ:GOOGL)'s Vice President of Data Centers, to its board of directors. This move, as noted by BMO Capital Markets, is expected to enhance Chemours' immersion cooling technology endeavors.

Despite reporting a net loss of $27 million in its Third Quarter 2024 Earnings Call, Chemours noted a 1% year-over-year increase in consolidated net sales to $1.5 billion. The company is actively managing its financial obligations while focusing on areas of growth and expansion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.